Clinical trials: Phase III
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
The objective of this study is to evaluate the effectiveness of SCTV01E in participants aged ≥18 years.
- Trial name
- NCT05308576
- Testing
- SCTV01E
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Vaccine
Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals.
- Trial name
- NCT07672626
- Testing
- the tested vaccine, the control vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
Periodontitis
Impact of Subgingival Instrumentation on Masticatory Performance and Psychological Distress
Patients of Stage III and Stage IV Periodontitis will be assessed for masticatory dysfunction and psychological distress. Subgingival Instrumentation will be done for treating periodontitis.
- Trial name
- NCT06024447
- Testing
- Subgingival Instrumentation
- Where
- India
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Herpes Zoster, Shingles
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
- Trial name
- NCT01505647
- Testing
- Zoster Vaccine, Live (AMP), Zoster Vaccine, Live
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Periodontitis, Polymorphism, Restriction Fragment Length
Vitamin D Receptor, Interleukin-1A and Interleukin-1B Gene Polymorphisms in Periodontitis
Background: The aim of the study is to find out the prevelance of VDR (rs731236), IL1B (rs1143634) and IL1A (rs1800587)gene polymorphisms in Turkish population and their association with stage III grade B / C periodontitis.
- Trial name
- NCT04806971
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Marmara University
Periodontitis
Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis
Chronic periodontitis is an infectious disease of periodontal support tissues caused by bacterial biofilm, which leads to inflammation and destruction of periodontal support tissues ultimately resulting in tooth loss.In the…
- Trial name
- NCT05530252
- Testing
- Oral biological antimicrobial gel, minocycline hydrochloride ointment, SRP
- Where
- China
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Beijing Stomatological Hospital, Capital Medical University
Breast Cancer Stage I, Breast Cancer Stage II
Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
Global cancer statistics by world region for the year 2022 estimated breast cancer the 2nd cause of new cancer cases (11.6%). (1) Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth…
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- NCT06950671
- Where
- Egypt
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rahma Esam Salama Esawi
Cervical Cancer, Anogenital Warts
Evaluation of Long Term Immunity Following HPV Vaccination
In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil®…
- Trial name
- NCT02276521
- Testing
- Cervarix®
- Where
- Fiji
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Pneumococcal Disease
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
- Trial name
- NCT07794748
- Testing
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Where
- 37 sites in United States
- Volunteers
- 4,670 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cholera
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the non-inferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine…
- Trial name
- Hillchol131 (NCT05732766)
- Testing
- Hillchol vaccine
- Where
- 9 sites in India
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Haemophilus Influenzae Type b (Hib) Infection
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age
- Trial name
- NCT01226953
- Testing
- Haemophilus influenzae type b (Hib) vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Flu, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.
- Conditions
- Influenza, Human, Flu, Human, Flu, Avian, Influenza
- Trial name
- NCT02107807
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 17 sites in Australia, Germany and 1 more
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Seqirus
Respiratory Syncytial Virus Infections
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in…
- Trial name
- NCT04732871
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 46 sites in United States, Finland and 3 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subject, Stage 0 Breast Cancer
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy.
- Conditions
- Healthy Subject, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT03050463
- Testing
- Biospecimen Collection, Functional Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Stanford University
Impression Cytology
Assessment of Intracellular Cytokines and Markers in Cells (Phase 3)
This is a single arm, prospective, bilateral, non-randomized study that will be split into four elements. Element 1 will be an in vitro non-clinical study and described in the laboratory protocol.
- Trial name
- NCT03896100
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Recurrent Clostridium Difficile Infection, Laboratory Confirmed Clostridium Difficile Infection
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
Recurrent CDI is a growing problem with few treatment options that provide lasting effect. Fecal transplantation has been shown in several case series to be successful in controlling recurrent CDI.
- Trial name
- NCT01226992
- Testing
- Vancomycin, Fecal Transplant
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Sexually Transmitted Diseases, Gonorrhea
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection
- Conditions
- Sexually Transmitted Diseases, Gonorrhea, Chlamydia
- Trial name
- EVOGUARD (NCT04553068)
- Testing
- EVO100
- Where
- 98 sites in United States
- Volunteers
- 1,892 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Healthy Volunteers
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to…
- Trial name
- TIDES (NCT02747927)
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 28 sites in Brazil, Colombia and 6 more
- Volunteers
- 20,099 people, healthy volunteers welcome
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.